Impossible for any board of a big pharma company to agree to pay that value for a company with barely US$200 million market cap.  Yes, I know Sanofi paid 7x for THOR...but I think the new CEO of Sanofi was a bit desperate to re-orient his company into Oncology...so he paid up for THOR.  Maybe his scientists "fell in love" with THOR...and we all know what love can do.  

For my thesis to be proved incorrect, the public markets need to value RVX at least $600 million...so more like $3 before a board says...Yah, we will cough up the extra dough.  Or someone at a big pharma company has to "fall in love with ABET/RVX".